| Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma SS Neelapu, FL Locke, NL Bartlett, LJ Lekakis, DB Miklos, CA Jacobson, ... New England Journal of Medicine 377 (26), 2531-2544, 2017 | 4942 | 2017 |
| ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells DW Lee, BD Santomasso, FL Locke, A Ghobadi, CJ Turtle, JN Brudno, ... Biology of blood and marrow transplantation 25 (4), 625-638, 2019 | 2294 | 2019 |
| Chimeric antigen receptor T-cell therapy—assessment and management of toxicities SS Neelapu, S Tummala, P Kebriaei, W Wierda, C Gutierrez, FL Locke, ... Nature reviews Clinical oncology 15 (1), 47-62, 2018 | 2124 | 2018 |
| Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial FL Locke, A Ghobadi, CA Jacobson, DB Miklos, LJ Lekakis, OO Oluwole, ... The lancet oncology 20 (1), 31-42, 2019 | 1943 | 2019 |
| Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors E Liu, D Marin, P Banerjee, HA Macapinlac, P Thompson, R Basar, ... New England Journal of Medicine 382 (6), 545-553, 2020 | 1601 | 2020 |
| Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study M Crump, SS Neelapu, U Farooq, E Van Den Neste, J Kuruvilla, J Westin, ... Blood, The Journal of the American Society of Hematology 130 (16), 1800-1808, 2017 | 1500 | 2017 |
| Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions Y Chung, S Tanaka, F Chu, RI Nurieva, GJ Martinez, S Rawal, YH Wang, ... Nature medicine 17 (8), 983-988, 2011 | 1190 | 2011 |
| Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma FL Locke, SS Neelapu, NL Bartlett, T Siddiqi, JC Chavez, CM Hosing, ... Molecular Therapy 25 (1), 285-295, 2017 | 675 | 2017 |
| Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial JR Westin, F Chu, M Zhang, LE Fayad, LW Kwak, N Fowler, J Romaguera, ... The lancet oncology 15 (1), 69-77, 2014 | 645 | 2014 |
| Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium LJ Nastoupil, MD Jain, L Feng, JY Spiegel, A Ghobadi, YI Lin, S Dahiya, ... Journal of Clinical Oncology 38 (27), 3119-3128, 2020 | 613 | 2020 |
| Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy EC Morris, SS Neelapu, T Giavridis, M Sadelain Nature Reviews Immunology 22 (2), 85-96, 2022 | 465 | 2022 |
| Double hit lymphoma: the MD A nderson C ancer C enter clinical experience Y Oki, M Noorani, P Lin, RE Davis, SS Neelapu, L Ma, M Ahmed, ... British journal of haematology 166 (6), 891-901, 2014 | 413 | 2014 |
| Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas Q Deng, G Han, N Puebla-Osorio, MCJ Ma, P Strati, B Chasen, E Dai, ... Nature medicine 26 (12), 1878-1887, 2020 | 391 | 2020 |
| Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial CA Jacobson, JC Chavez, AR Sehgal, BM William, J Munoz, G Salles, ... The lancet oncology 23 (1), 91-103, 2022 | 384 | 2022 |
| Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and … IF Khouri, P McLaughlin, RM Saliba, C Hosing, M Korbling, MS Lee, ... Blood, The Journal of the American Society of Hematology 111 (12), 5530-5536, 2008 | 373 | 2008 |
| Transcription factor achaete-scute homologue 2 initiates follicular T-helper-cell development X Liu, X Chen, B Zhong, A Wang, X Wang, F Chu, RI Nurieva, X Yan, ... Nature 507 (7493), 513-518, 2014 | 363 | 2014 |
| Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study K Takahashi, F Wang, H Kantarjian, D Doss, K Khanna, E Thompson, ... The lancet oncology 18 (1), 100-111, 2017 | 359 | 2017 |
| Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial M Wang, L Fayad, N Wagner-Bartak, L Zhang, F Hagemeister, ... The lancet oncology 13 (7), 716-723, 2012 | 347 | 2012 |
| Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial NH Fowler, RE Davis, S Rawal, L Nastoupil, FB Hagemeister, ... The Lancet Oncology 15 (12), 1311-1318, 2014 | 292 | 2014 |
| Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma FL Locke, JM Rossi, SS Neelapu, CA Jacobson, DB Miklos, A Ghobadi, ... Blood advances 4 (19), 4898-4911, 2020 | 288 | 2020 |
